Bimatoprost Versus Travoprost at Cairo University

Completed

• Conditions: Glaucoma; Ocular Hypertension

• Registration Number: NCT01092273
• Lead Sponsor: Cairo University

Brief Summary

Bimatoprost has been shown to provide effective IOP lowering in patients of all races. Conversely, travoprost has been shown to be more effective in black patients than in Caucasians in some studies. However, Noecker et al 2004 compared bimatoprost with travoprost in African-Americans with glaucoma or OHT, and found that bimatoprost was more likely than travoprost to achieve target pressure at 3 months.

These racial differences in efficacy of these medications warrant further investigations. The investigators study aim to compare the IOP-lowering efficacies of bimatoprost and travoprost in an Egyptian population with primary open-angle glaucoma (OAG) or ocular hypertension (OHT).

Detailed Description

Not available

Study Timeline

• Status Verified: 2008-01
• Study First Submitted: 2010-03-23
• Study First Submitted QC: 2010-03-23
• Last Update Submitted: 2010-03-23
• Study First Posted: 2010-03-24
• Last Update Posted: 2010-03-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Glaucoma and Ocular Hypertension

Exclusion Criteria

• Any ocular disease or medication that may raise the intraocular pressure.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of intraocular pressure lowering of bimatoprost versus travoprost.

Secondary Outcome Measures

Name	Time	Method
Rate of development of complications.

Trial Locations

Locations (1)

Cairo University; 🇪🇬 Cairo, Egypt